Subclinical Left Ventricular Dysfunction Prevention in Breast Cancer Patients after FAC Chemotherapy: A Carvedilol Trial

Astri Astuti, I Gede Sumantra, Adila Aafiyah, R. Maman Abdurahman, Teddy Arnold Sihite, Mohammad Rizki Akbar, Melawati Hasan, Erwan Martanto

Abstract


Objective:  To assess the cardioprotective effects of Carvedilol in preventing subclinical left ventricular dysfunction (SLVD) in breast cancer patients after completing FAC chemotherapy.

Methods: This prospective study employed a quasi-experimental clinical trial conducted from September 2018 to May 2019. Breast cancer patients receiving FAC chemotherapy were divided into two groups: intervention (IG) and control (CG). The IG received Carvedilol 6.25 mg b.i.d., which was increased every three weeks until reaching a tolerated dose. The study evaluated changes in left ventricular global longitudinal strain (GLS) and the incidence of SLVD (GLS reduction ≥15% and GLS >-18%) 24 weeks after initiating the FAC regimen.

Result: Of the 81 women enrolled in the study, 31 were in the IG. No significant changes in GLS were observed during or after completing FAC chemotherapy in the IG, whereas the CG showed contradictory results. At the end of the follow-up period, the delta GLS reduction was lower in the IG (0.7; 95% CI -0.60, 3.60) compared to the CG (3.00; 95% CI -2.16, 4.19), with a p-value of 0.035. Similarly, the percentage reduction in GLS was 3.6% in the IG and 14.29% in the CG, resulting in a p-value of 0.05. The incidence rate of SLVD (GLS reduction ≥15% and GLS > -18%) was lower in the IG (41.9% and 25.8%) than in the CG (58% and 48%).

Conclusion: Carvedilol may have a cardioprotective effect in preventing the incidence of SLVD, as evaluated by GLS reduction and changes, in women with breast cancer after completing a full cycle of the FAC regimen.


Keywords


Breast Cancer, Carvedilol, Chemotherapy, Fluorouracil–Adriamycin–Cyclophosphamide, Global Longitudinal Strain

Full Text:

PDF

References


  1. N Kamil, S Kamil. Global cancer incidences, causes and future predictions for Subcontinent Region. SRP. 2015 6(1):13–7. doi:10.5530/srp.2015.1.4
  2. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333-8. doi:10.1007/s12013-014-0459-6
  3. Azhar Y, Agustina H, Abdurahman M, Achmad D. Breast cancer in West Java: Where Do We Stand and go?. Indonesian J of Cancer. 2020;14(3):91. doi:10.33371/ijoc.v14i3.737
  4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  5. Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E. Braunwald’s Heart Disease : A Textbook of Cardiovascular Medicine. Eleventh edition. Elsevier/Saunders; 2019.
  6. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v8-v30. doi:10.1093/annonc/mdv298
  7. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9(1):e002661. doi:10.1161/CIRCHEARTFAILURE.115.002661
  8. Motoki H, Koyama J, Nakazawa H, Aizawa K, Kasai H, Izawa A, et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13(1):95–103. doi:10.1093/ejechocard/jer172
  9. Astuti A, Erwinanto E, Akbar MR, Martanto E, Badudu DF. Global and regional longitudinal strain reduction in breast cancer patients after first chemotherapy cycle with fluorouracil, adriamycin, and cyclophosphamide regimen. Cardiol Res. 2021;12(4):238–43. doi:10.14740/cr1229
  10. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375–80. doi:10.1016/j.amjcard.2011.01.006
  11. Kourek C, Touloupaki M, Rempakos A, Loritis K, Tsougkos E, Paraskevaidis I, et al. Cardioprotective Strategies from cardiotoxicity in cancer patients: a comprehensive review. J Cardiovasc Dev Dis. 2022;9(8):259. doi:10.3390/jcdd9080259
  12. Wibawa Martha J, Soedarsono DA, Iqbal M, Astuti A, Martanto E, Rizki Akbar M, et al. The effect of prophylactic carvedilol on subclinical left ventricular dysfunction after 1 cycle FAC chemotherapy in breast cancer patients. Int J Cardiol Heart Vasc. 2020;29:100575. doi:10.1016/j.ijcha.2020.100575
  13. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr.. 2014;27(9):911-39. doi:10.1016/j.echo.2014.07.012
  14. Abuosa AM, Elshiekh AH, Qureshi K, Abrar MB, Kholeif MA, Kinsara AJ, et al. Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin. Indian Heart J. 2018;70:S96-S100. doi:10.1016/j.ihj.2018.06.011
  15. Dulin B, Abraham WT. Pharmacology of carvedilol. Am J Cardiol. 2004;93(9A):3B-6B. doi:10.1016/j.amjcard.2004.01.003
  16. Leo B, Susie C, Kevin P , Benjamin W. Van T. A Systematic review of the beta-blockers carvedilol and metoprolol for the treatment of chronic heart failure. J of Pharmacol & Clin Res. 2017;3(1):555605. Doi: 10.19080/JPCR.2017.02.555605.
  17. Moshkani Farahani M, Nourian S, Jalalian HR, Khosravi A, Salesi M. Efficacy of Treatment with carvedilol in preventing early-stage left ventricular dysfunction in patients with breast cancer candidated to receive trastuzumab using 2D speckle-tracking echocardiography. Iranian Heart Journal. 2019;20(1):20-31.
  18. Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol J. 2014;21(5):509–15. doi:10.5603/CJ.a2013.0150
  19. Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G, Zarifian A, Homaei Shandiz F, Fazlinezhad A. Carvedilol Administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology. 2016;134(1):47-53. doi:10.1159/000442722
  20. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281–90. doi:10.1016/j.jacc.2018.02.049
  21. Jhorawat R, Kumari S, Varma SC, Rohit MK, Narula N, Suri V, et al. Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian J Med Res. 2016;144(5):725–9. doi:10.4103/ijmr.IJMR_1323_14
  22. Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity—a systematic review and meta-analysis of carvedilol. Heart Fail Rev. 2019;24(3):325–33. doi:10.1007/s10741-018-9755-3
  23. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, et al. Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023;16(3):269–78. doi: 10.1016/j.jcmg.2022.10.010




DOI: https://doi.org/10.15850/ijihs.v12.n1.3570

Article Metrics

Abstract view : 308 times
PDF - 86 times


 

This Journal indexed by

                   

 


Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License



View My Stats